Peptide Purity vs Net Peptide Content: How to Read a COA
Learn why HPLC purity and net peptide content are different measurements and how to verify what a peptide certificate actually reports.
Learn why HPLC purity and net peptide content are different measurements and how to verify what a peptide certificate actually reports.
Compare HPLC and LC-MS for peptide testing and learn what chromatographic purity, mass data and identity checks can show on a COA.
Read the 52-week tirzepatide SURMOUNT-OSA results, including the AHI endpoint and why the trials enrolled different PAP groups.
Learn how the retatrutide TRIUMPH-Outcomes trial differs from weight-loss trials and what its cardiovascular and kidney outcomes can show.
Find out what the 40-week retatrutide TRANSCEND-T2D-1 trial measured and how it differs from the TRIUMPH-2 obesity study.
Understand the tirzepatide SURMOUNT-1 study at 72 weeks, including its population, placebo comparison, outcomes and limitations.
Learn how tirzepatide activates GIP and GLP-1 receptors and what cell-based studies mean by imbalanced or biased agonism.
Understand the tirzepatide SURMOUNT-4 withdrawal design and why its week-88 results use week 36 as the comparison point.
Review what Lilly reported from TRIUMPH-3 in adults with severe obesity and cardiovascular disease, and what the trial measured.
Read the 80-week retatrutide TRIUMPH-2 results in adults with obesity or overweight and type 2 diabetes, with the placebo comparison.